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Background: This study compared the efficacy of the EX-PRESS® glaucoma filtration device 
and trabeculectomy in primary open-angle glaucoma up to five years after surgery.
Methods: Patients from a previously reported randomized, open-label, parallel-arm clinical 
trial in which 78 patients received either the EX-PRESS glaucoma filtration device or under-
went a trabeculectomy were followed for up to an additional four years (five total) beyond the 
original study (39 eyes per treatment group). Risk-benefit data were obtained for up to five years 
after glaucoma surgery. Outcome variables were intraocular pressures and intraocular pres-
sure medications. Complete success was denoted by intraocular pressure values # 18 mmHg 
without medication.
Results: The EX-PRESS glaucoma filtration device controlled intraocular pressure more 
effectively without medication for more patients from year 1 (86.8% versus 61.5%, P = 0.01) 
to year 3 (66.7% versus 41.0%, P = 0.02) than trabeculectomy. At year 1, only 12.8% of 
patients required intraocular pressure medication after EX-PRESS implantation, compared with 
35.9% after trabeculectomy. The proportions became closer at year 5 (41% versus 53.9%). The 
responder rate was higher with EX-PRESS and time to failure was longer. In addition, surgical 
interventions for complications were fewer after EX-PRESS implantation.
Conclusion: This five-year analysis confirmed and extended the results reported after one year. 
Compared with trabeculectomy, EX-PRESS provided better intraocular pressure control in the 
first three years, and patients required fewer intraocular pressure medications and fewer surgical 
interventions during the five-year study period. For patients with primary open-angle glaucoma, 
the EX-PRESS glaucoma filtration device, implanted under a superficial scleral flap, produced 
significantly higher success rates than trabeculectomy. EX-PRESS is an effective device for 
long-term treatment of primary open-angle glaucoma.
Keywords: glaucoma filtration device, trabeculectomy, primary open-angle glaucoma, 
  intraocular pressure, medication
Introduction
Open-angle glaucoma is a progressive optic neuropathy, resulting in loss of retinal 
ganglion cells leading to progressive damage of the visual field. Glaucoma is a leading 
cause of blindness in Western developed countries.1–3 Glaucoma treatments are directed 
at reducing intraocular pressure,4,5 either pharmacologically or surgically. Surgery is 
performed when intraocular pressure medication and laser treatment cease to control 
intraocular pressure.6 Trabeculectomy is the usual surgical procedure.7
An alternative procedure is to implant the EX-PRESS® glaucoma filtration 
device (Alcon Inc, Forth Worth, TX). The device is a small stainless steel, nonvalved Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  flow-restricting device, designed to lower intraocular 
  pressure in glaucomatous eyes.8 It was developed as a less 
invasive surgical procedure9,10 compared with conventional 
trabeculectomy, because it is inserted under a scleral flap 
to shunt aqueous humor from the anterior chamber to the 
subconjunctival space using a filtration bleb.11
Several studies have reported on the efficacy of 
  EX-PRESS,9,12–15 but only one randomized the surgical 
procedures.12 While the efficacy results consistently dem-
onstrated significant intraocular pressure reductions, they 
differed in the frequency of complications, with more such 
events occurring with earlier surgical techniques in which 
the EX-PRESS device was implanted under a conjunctival 
flap.9,14,15 Since then, the implantation procedure has evolved, 
and the EX-PRESS device is now implanted under a scleral 
flap with similar efficacy results,12,13 and the postoperative 
complication rates have improved considerably.
In the only prospective randomized trial published to date, 
de Jong12 randomized patients to either trabeculectomy or 
EX-PRESS and assessed the results one year after surgery. 
de Jong found better intraocular pressure control (P = 0.02) in 
patients implanted with EX-PRESS (12.0 mmHg) compared 
with trabeculectomy (13.9 mmHg), fewer prescriptions for 
intraocular pressure medications, and higher responder rates 
with intraocular pressure thresholds fixed at either 15 mmHg 
or 18 mmHg. Also, patients who received EX-PRESS 
implantation went significantly longer without the need for 
intraocular pressure medications.
Lifelong treatment of glaucoma is necessary to ensure 
intraocular pressure control and prevent disease progression. 
Hence documentation of treatment safety and long-term 
efficacy is essential. The present paper reports risk-benefit 
data at five years after glaucoma surgery from patients from 
the initial de Jong study.12
Methods
The study was conducted according to Dutch law and adhered 
to the tenets of the Helsinki Declaration. It was approved by 
the International Review Board at the  Academic Medical 
Centre, Amsterdam University. All patients gave written 
informed consent before   participating in the study.
The present analysis concerns data from the prospec-
tive randomized trial performed by de Jong.12 Patients were 
recruited at a single center (Amsterdam Academic Medical 
Center, Ophthalmology Department, The Netherlands). All 
glaucoma surgery was performed by one surgeon (LdJ) 
between October 2003 and November 2004.
Surgical details are described elsewhere.12 All surgeries 
were performed under topical anesthesia with Xylocaine® 
gel. Eyes randomized to EX-PRESS received the EX-PRESS 
R50®, a device developed for implantation under a scleral 
flap. The surgical procedures were similar in both treatment 
arms. During the whole procedure, only balanced salt solu-
tion was used to maintain or restore the anterior chamber, by 
injection through an additional corneal incision. No anterior 
chamber maintainer was used. A limbus-based conjunctival 
flap was dissected, followed by a “4 × 4 mm × half the scleral 
thickness” scleral flap dissected up to the clear cornea. For 
the eyes randomized to EX-PRESS, a preincision was made 
into the anterior chamber using a 27G needle parallel to the 
iris, followed by EX-PRESS device implantation. In the eyes 
randomized to trabeculectomy, a sclerotomy was performed 
associated with a peripheral iridectomy. Sutures were iden-
tical for both procedures. The scleral flap was then sutured 
using 10-0 nylon sutures. The number of nylon sutures used to 
close the scleral flap depended on the judgment of the amount 
of filtration by the surgeon. The conjunctiva was sutured over 
the limbus with one uninterrupted, single-running Vicryl 
suture. Postoperatively, corticosteroids were given six times 
a day, and if pressures were below 5 mmHg or the anterior 
chamber flattened, atropine1% twice daily was added. The 
steroids were tapered over six weeks according to the extent 
of wound healing. During the first week, postoperative anti-
biotics four times a day were added.
All eligible patients were 18 years old or older, and all pre-
sented with primary open-angle glaucoma not controlled by 
maximally tolerated intraocular pressure medication. Patients 
with other ocular diseases or previous ocular surgery (apart 
from cataract extraction) were excluded. Eligible patients 
were assigned to receive either a unilateral   EX-PRESS device 
inserted under a scleral flap or trabeculectomy, according to 
a computer-generated randomization list.
Optical assessments at baseline and at years 1, 2, 3, 4, and 
5 after surgery included Goldmann tonometry16 to measure 
intraocular pressure and the Early Treatment Diabetic Retin-
opathy Study chart for visual acuity.17 In addition, a daytime 
intraocular pressure profile was performed six months after 
surgery at 9 am, 11 am, 1 pm, and 4 pm.
Patients’ responses were classified as: intraocular pres-
sure values less than 15 mmHg and 18 mmHg thresholds; 
no subsequent intraocular pressure medication prescribed; 
and no further surgery performed for glaucoma   control. 
Three response criteria were defined, ie, “marginal   success” 
  (outcome 1), “partial success” (outcomes 1 and 2), and 
  “complete   success” (outcomes 1, 2, and 3). Topical   intraocular 
pressure medication was recorded at each visit. Overall 
intraocular pressure medication consumption and the average 
number of constituent medicinal entities (eg, DuoTrav® was Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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counted twice, as travoprost and timolol) were determined at 
annual assessments. Unscheduled visits to other eye clinics 
and eye surgeries were also recorded.
statistical analysis
According to the protocol, the primary response   criterion 
was failure rate at one year, defined as intraocular 
pressure $18 mmHg or the addition of an intraocular 
pressure-lowering medication. A sample of 40 patients per 
treatment group was needed to show a 32% difference, ie, 
EX-PRESS 15% versus trabeculectomy 47%, with alpha 
fixed at 5% and beta at 20% for a two-sided test.
All statistical analyses were performed using SAS 9.2 
(SAS Institute, Cary, NC). Between-group comparisons were 
performed using two-sample t-tests for normally distributed 
continuous variables. When the latter criteria did not apply, 
the Wilcoxon’s test, Fisher’s Exact test, or Chi-square adjusted 
test was performed, depending on the sample size.
Daytime intraocular pressure profiles were analyzed by a 
repeated mixed analysis of variance that included three factors, 
ie, treatment, time, and patients. All factors were fixed, except 
for patients (random), in a full two-order model. A similar model 
was constructed for the intraocular pressure analysis compar-
ing baseline with year 5   measurements. Complete, partial, and 
marginal success rates were   evaluated using Kaplan–Meier 
survival curves and the log-rank test. Age adjustment employed 
linear models. The analysis was conducted on patients given an 
EX-PRESS device or standard trabeculectomy to one eye, and 
followed up for five years. All tests were interpreted at 5%, two-
sided. No alpha   adjustment was made for test multiplicity.
Results
Seventy-eight patients (39 per treatment group) participated in 
the analysis. Table 1 presents the baseline sociodemographic 
data. Both groups were comparable except for age, whereby 
patients receiving the EX-PRESS were younger than those 
undergoing trabeculectomy.
Baseline mean intraocular pressure values did not differ 
significantly either with or without age adjustment (Table 2). 
After EX-PRESS devices were implanted, patients showed 
stable intraocular pressure values (P = 0.67) spanning year 1 
(12.0 mmHg) to year 5 (11.5 mmHg), whereas after trabeculec-
tomy, intraocular pressure values decreased (P , 0.0001) 
from year 3 (13.5 mmHg) to years 4 (11.8 mmHg) and 5 
(11.3 mmHg). Up to the end of year 3, intraocular pressure 
remained better controlled (P = 0.04) by EX-PRESS devices 
(intraocular pressure 12 mmHg) than by trabeculectomy 
(intraocular pressure 13.5 mmHg). During the remaining two 
years (to end of year 5) differences were not significant. Adjust-
ment of patient age did not modify these conclusions.
Table 3 presents daytime intraocular pressure profiles six 
months after surgery. Patients in the trabeculectomy group 
had two times more intraocular pressure-lowering drug pre-
scriptions.12 No time × treatment interaction was observed, 
indicating no corresponding time effect with either   treatment. 
The differences between the EX-PRESS device and trab-
eculectomy did not reach statistical significance (no age 
adjustment, P = 0.075; age-adjusted, P = 0.056).
Table 4 shows intraocular pressure correlation coef-
ficients for years 1–5 between intraocular pressure values 
at baseline and after cataract surgery. All correlation values 
were less than r = 0.4 (recognized as clinically significant18,19) 
and none was statistically significant. Hence, intraocular 
pressure control after glaucoma surgery was independent of 
initial intraocular pressure values.
Tables 5 and 6 compare the success rates after EX-PRESS 
implantation and trabeculectomy with two different intraocu-
lar pressure thresholds (ie, 15 mmHg and 18 mmHg). Success 
Table 1 Patient characteristics and study follow-up
EX-PRESS® Trabeculectomy P value
n % n %
gender Male 19 48.7 27 69.2 0.07
Female 20 51.3 12 30.8
race Caucasian 3 84.6 36 92.3 0.40
Black 4 10.3 3 7.7
Asian 2 5.1 0 0
glaucoma type POAg 37 94.9 39 100 0.49
PXFg 1 2.55 0 0
Pigmentary 1 2.55 0 0
Age Mean (sD) 62.4 (14.7) 68.6 (11.5) 0.04
range 26–86 37–83
Total follow-up (weeks) Mean (sD) 262.4 (4.0) 265.6 (13.8) 0.16
range 251.3–272.2 251.3–313.9
Abbreviations: sD, standard deviation; POAg, primary open-angle glaucoma; PXFg, pseudoexfoliation glaucoma.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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rates during years 1–3 after EX-PRESS were significantly 
higher for both thresholds, compared with trabeculectomy, 
without inclusion of medications. When medication efficacy 
was considered, differences did not reach statistical signifi-
cance, although EX-PRESS implantations continued to show 
higher success rates up to year 3.
Time to treatment failure according to the three different 
response criteria is depicted in Figure 1. With the 15 mmHg 
intraocular pressure threshold, EX-PRESS implantation 
produced significantly higher success rates than trabeculec-
tomy with all three criteria (Figures 1D, 1E, and 1F). When 
18 mmHg was the intraocular pressure threshold, the suc-
cess rate of   EX-PRESS implantation was again higher with 
all criteria, and significantly so for two criteria (Figures 1A 
and 1B).
The use of topical intraocular pressure medication is shown 
in Table 7. At all follow-up assessments, the likelihood of 
being prescribed an intraocular pressure medication was less 
after EX-PRESS implantation than after trabeculectomy.
Lastly, complications during the follow-up period 
  indicated that more surgical interventions followed trabeculec-
tomy than after EX-PRESS implantation.   Trabeculectomy 
patients experienced more needling (9 versus 3) and cataract 
surgery than EX-PRESS patients (8 versus 5).
Discussion
The present report is the first long-term efficacy comparison 
of trabeculectomy and the EX-PRESS glaucoma filtration 
device based on a randomized clinical trial. Patients implanted 
with EX-PRESS were more frequent responders, had better 
intraocular pressure control during the first three years, and 
fewer intraocular pressure drug prescriptions, compared with 
standard trabeculectomy. Thus, the results reported at one 
year by de Jong et al12 persisted beyond the initial follow-up 
period. The technical aspects of   EX-PRESS implantation and 
its short-term complications were discussed extensively in the 
former paper. This extension report confirms those points, 
except that subsequent surgical interventions for glaucoma 
were more frequent in the trabeculectomy group than in the 
EX-PRESS group.   However, the difference was not statisti-
cally significant because such events were rare and sample 
sizes were small.
The study was performed at a single center and all opera-
tions were by the same surgeon. Accordingly, the variance 
of our efficacy estimates may have been reduced by practice 
effects, thus increasing the sensitivity of the study to dif-
ferences between EX-PRESS implantation and standard 
trabeculectomy. This would limit the extrapolation of our 
results to other centers and countries.
However, the study can be compared with others on the 
basis of its trabeculectomy control group. First, the   intraocular 
pressure drug prescription rates after   trabeculectomy were close 
to those of Papaconstantinou et al,20 who reported a prescription 
rate of 0.5 items at six months, which is similar to the present rate 
of 0.74 items at one year. Second, Gedde et al21 reported a mean 
intraocular pressure of 13.3 ± 6.8 mmHg three years after trab-
eculectomy, which compares with the present 13.5 ± 3.3 mmHg 
with a similar number of prescribed drugs. Third, according 
to Geffen et al,22 intraocular pressure values ranged from 6 to 
21 mmHg (mean decrease 20%) four years after subconjunctival 
Table 2 Mean (± standard deviation) intraocular pressure values
IOP (mmHg) Without age adjustment Adjusted on age
EX-PRESS Trabeculectomy P value EX-PRESS Trabeculectomy P value
Before surgery 22.8 (8.0) 21.3 (5.6) 0.34 23.6 (7.0) 20.7 (7.0) 0.09
Year 1 12.0 (2.7) 13.9 (4.3) 0.02 12.2 (3.8) 13.9 (3.8) 0.05
Year 2 11.9 (2.9) 13.8 (3.2) 0.01 12.0 (3.3) 13.8 (3.2) 0.01
Year 3 12.0 (3.1) 13.5 (3.3) 0.04 12.1 (3.4) 13.5 (3.4) 0.08
Year 4 11.3 (2.5) 11.8 (2.4) 0.35 11.4 (2.5) 11.6 (2.5) 0.69
Year 5 11.5 (2.9) 11.3 (1.9) 0.73 11.4 (2.2) 11.2 (2.2) 0.71
Abbreviation: iOP, intraocular pressure.
Table 3 Daytime intraocular pressure profiles at six months after surgery
IOP after surgery  
at 6 months
Without age adjustment Age-adjusted
EX-PRESS Trabeculectomy EX-PRESS Trabeculectomy
9 am 10.6 11.5 11.8 12.6
11 am 10.7 11.8 12.0 12.9
1 pm 11.1 11.6 12.2 12.8
4 pm 11.1 11.7 12.1 13.0
Abbreviation: iOP, intraocular pressure.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table  4  Correlations  between  baseline  and  postoperative 
intraocular pressure measurements
Correlation with  
baseline IOP
EX-PRESS Trabeculectomy All patients
Year 1 r = 
P = 
-0.123 
0.46
-0.052 
0.75
-0.111 
0.34
Year 2 r = 
P = 
-0.14 
0.41
0.25 
0.12
0.023 
0.85
Year 3 r = 
P = 
0.029
0.87
0.150 
0.36
0.044 
0.70
Year 4 r = 
P = 
0.087 
0.60
0.191 
0.24
0.110 
0.34
Year 5 r = 
P = 
0.214 
0.20
-0.048 
0.77
0.140 
0.23
Abbreviation: iOP, intraocular pressure.
Table 5 intraocular pressure success rates (#18 mmhg)
IOP # 18  
mmHg
Without IOP medication Including IOP medication
EX-PRESS Trabeculectomy P value EX-PRESS Trabeculectomy P value
Year 1 86.8% 61.5% 0.01 100% 89.7% 0.06
Year 2 76.3% 51.3% 0.02 97.3% 92.3% 0.62
Year 3 66.7% 41.0% 0.02 97.4% 92.3% 0.62
Year 4 64.1% 46.2% 0.11 100% 100% 1.00
Year 5 59.0% 46.2% 0.25 97.4% 100% 0.49
Abbreviation: iOP, intraocular pressure.
topical lidocaine anesthesia and trabeculectomy without further 
glaucoma therapy or repeat filtration surgery, comparable with 
the present 46.2% after four years (although the success criteria 
differed slightly). Fourth, Gilmour et al23 reported a 42% suc-
cessful outcome (intraocular pressure , 18 mmHg, without 
intraocular pressure medication) at 40 months, similar to the 
present 41.0% success rate at three years. Lastly, Yalvac et al24 
observed complete success (intraocular pressure 6–21 mmHg, 
without medication) in 66.2% of eyes at six months after 
trabeculectomy and 55.1% at three years. Our corresponding 
findings were 61.5% at one year and 41.0% at three years, the 
latter discrepancy probably being explained by our 18 mmHg 
intraocular pressure threshold. The aforegoing results need to 
be confirmed by a multicenter, randomized, clinical trial for 
broader population inferences.
The present intraocular pressure effect of EX-PRESS 
implantation was approximately 1.5 mmHg greater than for 
trabeculectomy over three years, which is clinically relevant at 
a population level. Also, the standard deviation of   intraocular 
pressure was reduced after glaucoma surgery, indicating that 
EX-PRESS implantations provided good intraocular pressure 
control for most patients (ie, no outliers) and that the proce-
dure effectiveness is predictable. Furthermore, postoperative 
intraocular pressure values were independent of their baseline 
values, suggesting that even the most severe cases could 
benefit from such treatment and achieve intraocular pressure 
values of 11.5 mmHg at five years. Hence, intraocular pressure 
control using EX-PRESS is clinically relevant and predictable, 
and may be offered to even the most severe patients. Visual 
field measurements and quality of life effects should be 
investigated by future long-term trials.
The intraocular pressure benefits of EX-PRESS implanta-
tion, compared with standard trabeculectomy, persisted for 
three years and remained stable over five years. By contrast, 
standard trabeculectomy produced a lesser intraocular 
pressure reduction during the first three years, matching 
the   EX-PRESS intraocular pressure effect only at four and 
five years, on average. The difference may be explained by 
  trabeculectomy patients receiving more intraocular pres-
sure medication, with prescription adjustments, before 
they matched the intraocular pressure effect. Moreover, 
trabeculectomy patients required more needling during 
follow-up visits. The overall implication is that patients 
given EX-PRESS implantation may call upon fewer medi-
cal resources, which may generate savings compared with 
standard trabeculectomy. A full health   economics evaluation 
is needed for precise estimates.
Several limitations apply to this analysis. First, the physician 
knew which treatment was given when measuring intraocular 
pressure and writing intraocular pressure drug prescriptions, 
although intraocular pressure is a rather objective measure. 
Second, the study was limited to one center and surgeon, rais-
ing possible questions about practice effects, as discussed, and 
extrapolation to other populations. Third, patients were operated 
on one eye only, which introduces the possibility that intraocular 
pressure drugs instilled into the nonoperated eye might interact 
with the operated eye. Fourth, it may be questioned whether 
resources expended on intraocular pressure medication were 
truly stochastic variables, or driven by the protocol. Resources 
dedicated to control intraocular pressure after surgery might 
be different from those reported in this trial. Fifth, with the 
sample size fixed ad hoc, the observed number of patients does 
not allow reliable inferences concerning the incidence rates of 
long-term adverse events (eg, needling). Additional studies, Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Table 6 intraocular pressure success rates (#15 mmhg)
IOP # 15  
mmHg
Without IOP medication Including IOP medication
EX-PRESS Trabeculectomy P value EX-PRESS Trabeculectomy P value
Year 1 80.0% 51.3% 0.01 86.8% 76.9% 0.26
Year 2 71.1% 48.7% 0.046 89.2% 64.1% 0.01
Year 3 66.7% 38.5% 0.01 87.2% 79.5% 0.36
Year 4 61.5% 46.2% 0.17 94.9% 89.7% 0.24
Year 5 59.0% 46.2% 0.26 92.1% 94.9% 0.32
Abbreviation: iOP, intraocular pressure.
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Figure 1 survival curves comparing ex-Press implants with trabeculectomy. A) Kaplan–Meier life table curves of complete success (iOP # 18 mmhg): no iOP medication 
or subsequent glaucoma surgery (log-rank, p = 0.0049). B) Kaplan–Meier life table curves of partial success (iOP # 18 mmhg), i.e. including iOP medication: no subsequent 
glaucoma surgery (log-rank, p = 0.0085). C) Kaplan–Meier life table curves for marginal success (iOP # 18 mmhg) incorporating iOP medication and subsequent glaucoma 
surgery (log-rank, p = 0.18). D) Kaplan–Meier life table curves of complete success (iOP # 15 mmhg): no iOP medication or subsequent glaucoma surgery (log-rank, 
p = 0.0014). E) Kaplan–Meier life table curves of partial success (iOP # 15 mmhg) i.e. including iOP medication: no subsequent glaucoma surgery (log-rank, p = 0.0026). 
F) Kaplan–Meier life table curves of partial success (iOP # 15 mmhg) i.e. including iOP medication: no subsequent glaucoma surgery (log-rank, p = 0.0026).
recruiting larger samples and conducted at more centers, are 
needed to confirm the five-year results.
In conclusion, this five-year analysis confirmed the 
results presented at one year by de Jong et al.12 EX-PRESS 
implantations are more effective than standard trabeculectomy 
in controlling intraocular pressure during the first three years. 
This result was obtained with fewer subsequent surgical inter-
ventions and less topical intraocular pressure medication.Clinical Ophthalmology
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Table 7 intraocular pressure drug prescriptions
EX-PRESS Trabeculectomy
(n)% treated  
patients
Mean number of drugs  
(treated patients)
Mean number of  
drugs (all patients)
(n)% treated  
patients
Mean number of drugs  
(treated patients)
Mean number of  
drugs (all patients)
Year 1 (5) 12.8% 2.4 0.31 (14) 35.9% 2.1 0.74
Year 2 (9) 23.1% 2.1 0.49 (17) 43.6% 2.4 1.05
Year 3 (13) 33.3% 1.8 0.62 (21) 53.9% 2.4 1.28
Year 4 (14) 35.9% 1.9 0.69 (21) 53.9% 2.5 1.33
Year 5 (16) 41.0% 2.1 0.85 (21) 53.9% 2.0 1.10